您的当前位置:首页 > 行业数据 > BMS处于临床阶段的蛋白降解剂类核心管线
图片属性
图片格式:PNG 图片大小:150KB 图片尺寸:2344*775
同报告图片
 / 4
BMS处于临床阶段的蛋白降解剂类核心管线_第1页
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
BMS处于临床阶段的蛋白降解剂类核心管线_第2页
BMS处于临床阶段的蛋白降解剂类核心管线_第3页
BMS处于临床阶段的蛋白降解剂类核心管线_第4页
BMS处于临床阶段的蛋白降解剂类核心管线_第5页
所属报告: 医药健康行业研究:靶向蛋白降解:有望弥补抑制剂耐药和难成药靶点未满足需求-241017(48页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠